Response to Rosário and Souza Côrtes re: “The De Novo Detection of Anti-Thyroglobulin Antibodies and Differentiated Thyroid Cancer Recurrence”

Thyroid ◽  
2020 ◽  
Vol 30 (11) ◽  
pp. 1686-1687 ◽  
Author(s):  
Ngwe Yin ◽  
Steven I. Sherman ◽  
Youngju Pak ◽  
Danielle R. Litofsky ◽  
Andrew G. Gianoukakis ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
De Novo ◽  
Cancer Recurrence ◽  
Thyroglobulin Antibodies ◽  
Thyroid Cancer Recurrence

scholarly journals The De Novo Detection of Anti-Thyroglobulin Antibodies and Differentiated Thyroid Cancer Recurrence

Thyroid ◽  
2020 ◽  
Vol 30 (10) ◽  
pp. 1490-1495 ◽  
Author(s):  
Ngwe Yin ◽  
Steven I. Sherman ◽  
Youngju Pak ◽  
Danielle R. Litofsky ◽  
Andrew G. Gianoukakis ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
De Novo ◽  
Cancer Recurrence ◽  
Thyroglobulin Antibodies ◽  
Thyroid Cancer Recurrence

scholarly journals Significance of “de novo” appearance of thyroglobulin antibodies in patients with differentiated thyroid cancer

2020 ◽  
Vol 35 (3) ◽  
pp. 41-49
Author(s):  
Lorenzo Scappaticcio ◽  
Pierpaolo Trimboli ◽  
Frederik A. Verburg ◽  
Luca Giovanella
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
De Novo ◽  
Disease Free Survival ◽  
Thyroglobulin Antibodies ◽  
Free Survival ◽  
Similar Disease ◽  
Structural Disease ◽  
Disease Free

Objective Clinical and laboratory guidelines recommend thyroglobulin antibodies (TgAbs) measurement with every thyroglobulin (Tg) measurement for the follow-up of differentiated thyroid cancer (DTC) patients. However, no evidence exists on the need for perpetual TgAbs testing in patients who are TgAb-negative at baseline. Our study was carried out to evaluate the prevalence, the dynamic changes, and the clinical significance of TgAbs that appeared de novo during the follow-up of DTC patients who were TgAb-negative at baseline. Methods The data of DTC patients with negative pre-ablation TgAbs were reviewed retrospectively. The main characteristics of patients with both transient and sustained de novo TgAbs appearance were analyzed. DTC patients with persistently negative TgAbs served as controls. Results Among 119 patients with pre-ablation negative TgAbs, 14 cases (11.7%) with de novo TgAbs appearance (10 and 4 patients with a transient and sustained de novo TgAbs appearance, respectively) were detected. No differences in disease-free survival were observed in patients with de novo TgAbs appearance compared to controls. The TgAbs peak value was higher in patients with sustained de novo appearance compared to patients with transient de novo. Two of 14 patients with de novo TgAbs developed structural disease with concurrently detectable Tg in both cases. Conclusions Transient de novo TgAbs appearance is not infrequent during DTC patients’ follow-up, and it has no apparent clinical impact. Sustained de novo TgAbs appearance is rare and may predict structural recurrences; however, similar disease-free survival was observed in patients with sustained de novo TgAbs and TgAb-negative DTC patients.

scholarly journals Preoperative charcoal suspension tattoo for the detection of differentiated thyroid cancer recurrence

2019 ◽  
Author(s):  
Francesco Soprani ◽  
Andrea De Vito ◽  
Fabio Bondi ◽  
Giuseppe Magliulo ◽  
Soon Rene ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Cancer Recurrence ◽  
Thyroid Cancer Recurrence

scholarly journals Effectiveness of Different Thyroid Stimulating Hormone Thresholds for Thyroid Hormone Withdrawal - Aided Radioiodine Ablation in Patients With Differentiated Thyroid Cancer: A Systematic Review and Meta - Analysis

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. A860-A860
Author(s):  
Tatiana Rojas ◽  
Paola Solis-Pazmino ◽  
Eddy Lincango-Naranjo ◽  
Tannya Ledesma ◽  
Benjamin Alvarado-Mafla ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Meta Analysis ◽  
Cancer Recurrence ◽  
Thyroid Stimulating Hormone ◽  
Risk Of Bias ◽  
Thyroid Hormone Withdrawal ◽  
Radioiodine Ablation ◽  
Thyroid Cancer Recurrence ◽  
Stimulating Hormone

Abstract Background: Patients with differentiated thyroid cancer (DTC) may benefit of radioiodine ablation (RAI) to reduce the probability of thyroid cancer recurrence. Guidelines recommend that thyroid stimulating hormone (TSH) of >30mIU/L before RAI to optimize treatment response. However, evidence regarding this recommendation is conflicting. We conducted a systematic review and meta-analysis to compare outcomes (thyroid cancer recurrence and survival at 10 years of follow up) of stimulated TSH threshold before RAI with primary analysis focus on <30 mIU/L versus ≥30 mIU/L, and subgroup analysis on <90 mIU/L versus ≥90 mIU/L in patients with DTC after initial total thyroidectomy. Methods: The protocol for this study is registered and available online (CRD42020158354). Briefly, we searched several databases from their inception to April 2020. Reviewers, working independently and in duplicate selected studies for inclusion, extracted data, and evaluated each study’s risk of bias. We excluded studies that used recombinant human thyroid stimulating hormone before ablation. Results: We included five retrospective cohort studies, which enrolled a total of 2,514 patients. Risk of bias was low in four studies and high in one study. Mean age was 47 years old (ranged from 40.7 to 47.9) and most of them were female (69%). The most common DTC type was papillary thyroid cancer (78%). From those articles that reported tumor characteristics, 48% had a size ≤2cm (T1b) and 47% >2cm. Moreover, 73% of the patients had no regional lymph metastasis (N0). Two studies reported radioiodine mean dose given of 30 and 100 mci. A total of 301 patients were included in the TSH threshold <30 mIU/L group and 1788 patients in the TSH ≥30 mIU/L group. Comparing stimulated TSH threshold before RAI (<30 mIU/L versus ≥30 mIU/L), there was difference in recurrence at 1 year (RR 2.46 (C.I. 1.09-5.55) and at 20 years (RR 1.71 (C.I. 1.19 – 2.47). However, there was no difference in mortality at 20 years (RR 0.53 (Confidence Interval (C.I.) 0.12-2.23). In addition, 10-years recurrence was not different when we compared <90 mIU/L versus ≥90 mIU/L TSH (RR 1.06; 95%CI: 0.88 – 1.27). Conclusions: Mortality do not differ between recommended TSH goal (≥30 mIU/L) vs <30 mIU/L in thyroid hormone withdrawal-aided radioiodine ablation in DTC patients. However, the risk of recurrence is reduced when patients achieved a TSH level >30 UI/mL. These results suggest that patients may need to reach a stimulated TSH ≥30 mIU/L stimulated TSH threshold to be treated. Randomized trials are needed to confirm these findings.

scholarly journals The Delayed Risk Stratification System in the Risk of Differentiated Thyroid Cancer Recurrence

PLoS ONE ◽  
2016 ◽  
Vol 11 (4) ◽  
pp. e0153242 ◽  
Author(s):  
Aldona Kowalska ◽  
Agnieszka Walczyk ◽  
Iwona Pałyga ◽  
Danuta Gąsior-Perczak ◽  
Klaudia Gadawska-Juszczyk ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Risk Stratification ◽  
Differentiated Thyroid Cancer ◽  
Cancer Recurrence ◽  
Stratification System ◽  
Thyroid Cancer Recurrence ◽  
Risk Stratification System

scholarly journals Physician Confidence in Neck Ultrasonography for Surveillance of Differentiated Thyroid Cancer Recurrence

2020 ◽  
Author(s):  
Kevin J. Kovatch ◽  
David Reyes-Gastelum ◽  
Jennifer A. Sipos ◽  
Elaine M. Caoili ◽  
Ann S. Hamilton ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Cancer Recurrence ◽  
Thyroid Cancer Recurrence

Accuracy of positron emission tomography and positron emission tomography-CT in the detection of differentiated thyroid cancer recurrence with negative131I whole-body scan results: A meta-analysis

Head & Neck ◽  
2015 ◽  
Vol 38 (2) ◽  
pp. 316-327 ◽  
Author(s):  
Rosângela Caetano ◽  
Cláudia Regina Garcia Bastos ◽  
Ione Ayala Gualandi de Oliveira ◽  
Rondineli Mendes da Silva ◽  
Clarisse Pereira Dias Drumond Fortes ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Meta Analysis ◽  
Cancer Recurrence ◽  
Emission Tomography ◽  
Whole Body ◽  
Whole Body Scan ◽  
Positron Emission ◽  
Thyroid Cancer Recurrence
Sign in / Sign up

Export Citation Format

Share Document